H. Lundbeck gets antitrust OK on Chelsea buyout; Pfizer among best at banking offshore profits; Hamburg gets a new boss;

@FiercePharma: Ranbaxy decision shows why FDA reluctant to rely on European inspections. More | Follow @FiercePharma

@TracyStaton: Would you pay $84K for Sovaldi yourself if you had hep C? LinkedIn discussion | Follow @TracyStaton

@EricPFierce: More action in sterile injectables. Amneal said to be trying to buy India's Epsilon Pharmaceuticals. Story | Follow @EricPFierce

@CarlyHFierce: Still trending on FierceVaccines: The top 10 best-selling vaccines of 2013. Report | Follow @CarlyHFierce

@JustinHFierce: Because mad cow disease is scary, when you actually think about it. Article | Follow @JustinHFierce

> FDA Commissioner Margaret Hamburg has a new boss after the Senate Thursday confirmed Sylvia Mathews Burwell, the former director of the OMB, as the head of the Department of Health and Human Services. Story

> China-focused Luqa Pharmaceuticals is now selling drugs in Hong Kong. Release

> Chelsea Therapeutics ($CHTP) announced that the waiting period under the Hart-Scott-Rodino Antitrust Act has expired, indicating U.S. regulators see no reason its merger with H. Lundbeck should not go forward. Release

> A new report says Pfizer ($PFE) last year ranked third of all the Fortune 500 companies when it comes to booking profits in offshore havens with $69 billion booked in foreign subsidiaries. Story

> Strides Arcolab has gotten FDA approval to market methoxsalen capsules for treating psoriasis, eczema and vitiligo skin disease. Story

> An advocacy group has complained to the FDA about a web page for a Novartis ($NVS) product called Denagard, an antibiotic it is promoting for treating dysentery and pneumonia and intestinal infections in swine. Blog post

Medical Device News

@FierceMedDev: London's Institute of Cancer Research to help develop MRI-guided radiation systems. More | Follow @FierceMedDev

@VarunSaxena2: A working group recommended $4.5 billion over 12 years in funding for NIH's BRAIN initiative. Story | Follow @VarunSaxena2

@MichaelGFierce: Singapore team designs nanotechnology glaucoma treatment for sustained release. Article | Follow @MichaelGFierce

@EmilyWFierce: New test that pinpoints multiple genes in a tumor could replace companion Dx as a tool for diagnosing cancer. Story | Follow @EmilyWFierce

> FDA beefs up cybersecurity efforts to ensure safety standards. More

> Kleiner Perkins, TPG-backed heart transplant monitor company files for $50M IPO. Story

Biotech News

@FierceBiotech: The search is on for 2014's Fiercest biotech startups. More | Follow @FierceBiotech

@JohnCFierce: ICYMI: Trevi, Complexa bag $38M in VC cash to hit the gas on R&D. Story | Follow @JohnCFierce

@DamianFierce: Follow @FiercePharma as @EricPFierce and @JonEPVantage wrap #ASCO14. Or tune in here: Twitter chat | Follow @DamianFierce

@EmilyMFierce: Collaborative KPI Therapeutics launches to beef up Kineta's pipeline. Article | Follow @EmilyMFierce

> Merck exec joins Novartis to helm oncology unit. Chutes & Ladders

> GW hits the FDA fast track with its cannabis-based epilepsy drug. More

> Pfenex eyes a $75M IPO to bankroll its biosimilars. Article

And Finally... A new review of past clinical trials finds that when treating women for acne, birth control pills work better than antibiotics. Story